Detalles de la búsqueda
1.
Relationship between reasons for intermittent missing patient-reported outcomes data and missing data mechanisms.
Qual Life Res
; 2024 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38879861
2.
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
Haematologica
; 105(12): 2879-2882, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33256392
3.
Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
Am J Hematol
; 92(10): E611-E614, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28707398
4.
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.
Hemasphere
; 7(9): e940, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37663673
Resultados
1 -
4
de 4
1
Próxima >
>>